{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:39:10Z","timestamp":1763545150223,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":36,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071627716"},{"type":"electronic","value":"9781071627723"}],"license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-2772-3_26","type":"book-chapter","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T18:07:03Z","timestamp":1668794823000},"page":"495-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy"],"prefix":"10.1007","author":[{"given":"Christine","family":"P\u00e9ladeau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard J.","family":"Jasmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"26_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1750-3639.2009.00275.x","volume":"20","author":"SM Baby","year":"2010","unstructured":"Baby SM, Bogdanovich S, Willmann G et al (2010) Differential expression of utrophin-A and -B promoters in the central nervous system (CNS) of normal and dystrophic mdx mice. Brain Pathol 20:323\u2013342","journal-title":"Brain Pathol"},{"key":"26_CR2","doi-asserted-by":"publisher","first-page":"14025","DOI":"10.1073\/pnas.96.24.14025","volume":"96","author":"EA Burton","year":"1999","unstructured":"Burton EA, Tinsley JM, Holzfeind PJ et al (1999) A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 96:14025\u201314030","journal-title":"Proc Natl Acad Sci U S A"},{"key":"26_CR3","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/nar\/24.9.1646","volume":"24","author":"CL Dennis","year":"1996","unstructured":"Dennis CL, Tinsley JM, Deconinck AE et al (1996) Molecular and functional analysis of the utrophin promoter. Nucleic Acids Res 24:1646\u20131652","journal-title":"Nucleic Acids Res"},{"key":"26_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1083\/jcb.115.6.1695","volume":"115","author":"TM Nguyen","year":"1991","unstructured":"Nguyen TM, Ellis JM, Love DR et al (1991) Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines. J Cell Biol 115:1695\u20131700","journal-title":"J Cell Biol"},{"key":"26_CR5","doi-asserted-by":"publisher","first-page":"45285","DOI":"10.1074\/jbc.M205177200","volume":"277","author":"AP Weir","year":"2002","unstructured":"Weir AP, Burton EA, Harrod G et al (2002) A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. J Biol Chem 277:45285\u201345290","journal-title":"J Biol Chem"},{"key":"26_CR6","doi-asserted-by":"crossref","unstructured":"Nakamura A, Takeda S. Mammalian models of Duchenne muscular dystrophy: pathological characteristics and therapeutic applications. https:\/\/www.hindawi.com\/journals\/bmri\/2011\/184393\/","DOI":"10.1155\/2011\/184393"},{"key":"26_CR7","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1093\/hmg\/ddr105","volume":"20","author":"A Goyenvalle","year":"2011","unstructured":"Goyenvalle A, Seto JT, Davies KE et al (2011) Therapeutic approaches to muscular dystrophy. Hum Mol Genet 20:R69\u2013R78","journal-title":"Hum Mol Genet"},{"key":"26_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0959-437X(02)00309-X","volume":"12","author":"M Durbeej","year":"2002","unstructured":"Durbeej M, Campbell KP (2002) Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev 12:349\u2013361","journal-title":"Curr Opin Genet Dev"},{"key":"26_CR9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1096\/fj.04-1956rev","volume":"19","author":"JV Chakkalakal","year":"2005","unstructured":"Chakkalakal JV, Thompson J, Parks RJ et al (2005) Molecular, cellular, and pharmacological therapies for Duchenne\/Becker muscular dystrophies. FASEB J 19:880\u2013891","journal-title":"FASEB J"},{"key":"26_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00109-003-0484-1","volume":"82","author":"S Bogdanovich","year":"2004","unstructured":"Bogdanovich S, Perkins KJ, Krag TOB et al (2004) Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. J Mol Med 82:102\u2013115","journal-title":"J Mol Med"},{"key":"26_CR11","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1085","volume":"10","author":"P Gregorevic","year":"2004","unstructured":"Gregorevic P, Blankinship MJ, Allen JM et al (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10:828\u2013834","journal-title":"Nat Med"},{"key":"26_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/mt.2008.28","volume":"16","author":"P Gregorevic","year":"2008","unstructured":"Gregorevic P, Blankinship MJ, Allen JM et al (2008) Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther 16:657\u2013664","journal-title":"Mol Ther"},{"key":"26_CR13","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1093\/hmg\/ddt342","volume":"22","author":"LR Rodino-Klapac","year":"2013","unstructured":"Rodino-Klapac LR, Janssen PML, Shontz KM et al (2013) Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Hum Mol Genet 22:4929\u20134937","journal-title":"Hum Mol Genet"},{"key":"26_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","volume":"34","author":"S Guiraud","year":"2017","unstructured":"Guiraud S, Davies KE (2017) Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr Opin Pharmacol 34:36\u201348","journal-title":"Curr Opin Pharmacol"},{"key":"26_CR15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1517\/21678707.2015.1088780","volume":"3","author":"J Ramos","year":"2015","unstructured":"Ramos J, Chamberlain JS (2015) Gene therapy for Duchenne muscular dystrophy. Expert Opin Orphan Drugs 3:1255\u20131266","journal-title":"Expert Opin Orphan Drugs"},{"key":"26_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/mt.2008.149","volume":"16","author":"GL Odom","year":"2008","unstructured":"Odom GL, Gregorevic P, Allen JM et al (2008) Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin\/utrophin-deficient mice. Mol Ther 16:1539\u20131545","journal-title":"Mol Ther"},{"key":"26_CR17","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1093\/hmg\/ddv154","volume":"24","author":"S Guiraud","year":"2015","unstructured":"Guiraud S, Squire SE, Edwards B et al (2015) Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet 24:4212\u20134224","journal-title":"Hum Mol Genet"},{"key":"26_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019189","volume":"6","author":"JM Tinsley","year":"2011","unstructured":"Tinsley JM, Fairclough RJ, Storer R et al (2011) Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One 6:e19189","journal-title":"PLoS One"},{"key":"26_CR19","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1093\/hmg\/11.26.3333","volume":"11","author":"S Squire","year":"2002","unstructured":"Squire S, Raymackers JM, Vandebrouck C et al (2002) Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum Mol Genet 11:3333\u20133344","journal-title":"Hum Mol Genet"},{"key":"26_CR20","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/4033","volume":"4","author":"J Tinsley","year":"1998","unstructured":"Tinsley J, Deconinck N, Fisher R et al (1998) Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4:1441\u20131444","journal-title":"Nat Med"},{"key":"26_CR21","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1096\/fj.201800081R","volume":"32","author":"C P\u00e9ladeau","year":"2018","unstructured":"P\u00e9ladeau C, Adam NJ, Jasmin BJ (2018) Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression. FASEB J 32:5090\u20135103","journal-title":"FASEB J"},{"key":"26_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/hmg\/ddv444","volume":"25","author":"C P\u00e9ladeau","year":"2016","unstructured":"P\u00e9ladeau C, Ahmed A, Amirouche A et al (2016) Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles. Hum Mol Genet 25:24\u201343","journal-title":"Hum Mol Genet"},{"key":"26_CR23","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41467-020-15971-w","volume":"11","author":"C P\u00e9ladeau","year":"2020","unstructured":"P\u00e9ladeau C, Adam N, Bronicki LM et al (2020) Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles. Nat Commun 11:1990","journal-title":"Nat Commun"},{"key":"26_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/hmg\/ddu535","volume":"24","author":"H Al-Rewashdy","year":"2015","unstructured":"Al-Rewashdy H, Ljubicic V, Lin W et al (2015) Utrophin A is essential in mediating the functional adaptations of mdx mouse muscle following chronic AMPK activation. Hum Mol Genet 24:1243\u20131255","journal-title":"Hum Mol Genet"},{"key":"26_CR25","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/hmg\/ddr265","volume":"20","author":"V Ljubicic","year":"2011","unstructured":"Ljubicic V, Miura P, Burt M et al (2011) Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum Mol Genet 20:3478\u20133493","journal-title":"Hum Mol Genet"},{"key":"26_CR26","doi-asserted-by":"publisher","first-page":"C66","DOI":"10.1152\/ajpcell.00357.2013","volume":"307","author":"V Ljubicic","year":"2014","unstructured":"Ljubicic V, Burt M, Lunde JA et al (2014) Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1\u03b1 axis. Am J Physiol Cell Physiol 307:C66\u2013C82","journal-title":"Am J Physiol Cell Physiol"},{"key":"26_CR27","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1093\/hmg\/ddp431","volume":"18","author":"P Miura","year":"2009","unstructured":"Miura P, Chakkalakal JV, Boudreault L et al (2009) Pharmacological activation of PPAR\u03b2\/\u03b4 stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum Mol Genet 18:4640\u20134649","journal-title":"Hum Mol Genet"},{"key":"26_CR28","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1093\/hmg\/ddt165","volume":"22","author":"A Amirouche","year":"2013","unstructured":"Amirouche A, Tadesse H, Lunde JA et al (2013) Activation of p38 signaling increases utrophin A expression in skeletal muscle via the RNA-binding protein KSRP and inhibition of AU-rich element-mediated mRNA decay: implications for novel DMD therapeutics. Hum Mol Genet 22:3093\u20133111","journal-title":"Hum Mol Genet"},{"key":"26_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.clnu.2012.06.003","volume":"32","author":"BS Gordon","year":"2013","unstructured":"Gordon BS, Delgado D\u00edaz DC, Kostek MC (2013) Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy. Clin Nutr 32:104\u2013111","journal-title":"Clin Nutr"},{"key":"26_CR30","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1096\/fj.12-215723","volume":"27","author":"S Vianello","year":"2013","unstructured":"Vianello S, Yu H, Voisin V et al (2013) Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy. FASEB J 27:2256\u20132269","journal-title":"FASEB J"},{"key":"26_CR31","doi-asserted-by":"crossref","unstructured":"Wishart DS, Feunang YD, Guo AC et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. 46:D1074\u2013D1082","DOI":"10.1093\/nar\/gkx1037"},{"key":"26_CR32","doi-asserted-by":"crossref","unstructured":"Jahnke VE, Van Der Meulen JH, Johnston HK et al (2012) Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. 2:16","DOI":"10.1186\/2044-5040-2-16"},{"key":"26_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/mus.24692","volume":"52","author":"V Ljubicic","year":"2015","unstructured":"Ljubicic V, Jasmin BJ (2015) Metformin increases peroxisome proliferator-activated receptor \u03b3 Co-activator-1\u03b1 and utrophin a expression in dystrophic skeletal muscle. Muscle Nerve 52:139\u2013142","journal-title":"Muscle Nerve"},{"key":"26_CR34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4103\/0976-500X.119726","volume":"4","author":"J Charan","year":"2013","unstructured":"Charan J, Kantharia ND (2013) How to calculate sample size in animal studies? J Pharmacol Pharmacother 4:303\u2013306","journal-title":"J Pharmacol Pharmacother"},{"key":"26_CR35","doi-asserted-by":"crossref","unstructured":"Love DR, Hill DF, Dickson G et al (1989) An autosomal transcript in skeletal muscle with homology to dystrophin. 339:55\u201358","DOI":"10.1038\/339055a0"},{"key":"26_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1242\/dmm.018424","volume":"8","author":"JW McGreevy","year":"2015","unstructured":"McGreevy JW, Hakim CH, McIntosh MA et al (2015) Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech 8:195\u2013213","journal-title":"Dis Model Mech"}],"container-title":["Methods in Molecular Biology","Muscular Dystrophy Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2772-3_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T07:08:05Z","timestamp":1677654485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2772-3_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"ISBN":["9781071627716","9781071627723"],"references-count":36,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2772-3_26","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"19 November 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}